Introduction
============

Defecation disorders such as fecal incontinence (FI) and constipation are common and often underreported. The estimated prevalence of constipation in the general population is approximately 15%, while the estimated prevalence is 6--11% for FI.[@b1-jnm-25-159],[@b2-jnm-25-159] Fecal disorders are accompanied by embarrassment, shame and depression. This leads to impairment in patients' quality of life (QoL), as defecation habits tend to control both personal and social lifestyles. In addition, FI and constipation impose a significant healthcare burden.[@b3-jnm-25-159]

Over the last 2 decades, neuromodulation has become an accepted treatment for FI and to some extent also for constipation. Sacral neuromodulation (SNM) is a minimally invasive treatment involving continuous, pulsating electrical stimulation of the sacral nerves. SNM is therefore also called sacral nerve stimulation (SNS). The exact mechanism of action of SNM is not yet fully understood. Studies have demonstrated both a direct effect on the sphincter muscle[@b4-jnm-25-159]--[@b6-jnm-25-159] and modulation of spinal and supraspinal functions.[@b7-jnm-25-159],[@b8-jnm-25-159]

The short- and mid-term success of SNM in patients with FI has been demonstrated in several studies.[@b9-jnm-25-159]--[@b11-jnm-25-159] Recently, studies with long-term follow-up have shown a lasting effect.[@b12-jnm-25-159]--[@b14-jnm-25-159] Data regarding constipation are rare, particularly data with a long-term follow-up. Despite initial success, the role of SNM for constipation is still debated.[@b15-jnm-25-159],[@b16-jnm-25-159] A further challenge is to investigate the long-term adverse events and the efforts required to maintain SNM. Surgical reintervention rates are high, increase over time and are likely to be underreported.[@b17-jnm-25-159]--[@b19-jnm-25-159]

The aim of this study was to assess the sustainability of SNM success in patients with FI and constipation. Additionally, the rates of adverse events and reinterventions were recorded, and the effects of adverse events and reintervention on treatment success were evaluated.

Materials and Methods
=====================

Study Design and Participants
-----------------------------

This is a retrospective, single center analysis of a prospectively maintained database.

All patients who underwent invasive neuromodulation (n = 115) at the surgical department of the Kantonsspital St. Gallen in Switzerland from February 2006 to October 2015 were prospectively registered in the Swiss Registry of Sacral Neuromodulation. The study was approved by the Institutional Review Board at the Ethikkommission Ostschweiz (BASEC No. 2016-00585) and was registered at [clinicaltrials.gov](http://clinicaltrials.gov) with the identifier NCT02836717.

The patients were informed at the start of the therapy that their data would be recorded in a registry. They were asked for their consent for registering, analyzing and performing a quality assessment of their data. After obtaining informed consent, patients older than 18 years of age who received SNM therapy due to chronic FI or constipation after unsuccessful conservative treatment were included in the study. Some patients underwent previous surgical treatment such as sphincteroplasty (n = 11), levatoroplasty (n = 1), or rectopexy (n = 2). Two patients were excluded because they did not provide consent for data evaluation. Ten patients were excluded because they received pudendal nerve stimulation, and 2 patients were excluded because the indication for SNM therapy was pelvic pain without FI or constipation.

Study Procedures
----------------

All patients underwent a systematic workup before they were enrolled in SNM screening. At the baseline visit, each patient's underlying diagnosis and previous therapies were documented. Furthermore, an endoanal ultrasound and an anorectal manometry were part of the workup. Both investigations could not be recorded in the SNM registry and for this reason were not assessed. For patients with FI, the Wexner score (Cleveland clinic incontinence score),[@b20-jnm-25-159] the number of involuntary evacuations per week and the ability to defer defecation were recorded. Patients were asked to complete the Fecal Incontinence Quality of Life (FIQL) questionnaire.[@b21-jnm-25-159] Patients with constipation recorded their bowel movements in a diary. Furthermore, colon transit time was routinely assessed by radiography. Because these data could not be recorded in the SNM registry, the therapeutic success for constipation was only assessed by subjective symptom improvement.

SNM therapy was initiated by implanting a permanent electrode (tined lead; Medtronic, Minneapolis, Minnesota, USA). If possible, nerve evaluation at both sacral foramina 3 (S3) and S4 was performed. The electrode was implanted at the foramen with the best sensory or motor response. During the screening phase, the electrode was connected to an extracorporeal stimulator and was adjusted weekly. If constipation or FI symptoms were reduced by more than 50%, the screening was considered successful and an internal permanent pulse generator (IPG) (InterStim I or II; Medtronic) was implanted. SNM therapy was considered successful if it was ongoing and the patient reported sustained subjective symptom improvement in either FI or constipation. The patient's subjective evaluation of symptom improvement was the only factor that was used to define success. Further information was used to objectify but not define SNM success, including the Wexner score, the number of involuntary evacuations per week, the ability to defer defecation and the FIQL.

Follow-up occurred regularly 1, 3, and 6 months after implantation, followed by annual evaluations. During each visit, the battery status, electrode function, and current programming were evaluated and adjusted if necessary. Additional therapies and subjective symptom improvements were recorded, and an FIQL questionnaire was distributed. For all patients with FI, the Wexner score, the number of involuntary evacuations per week and the ability to defer defecation were documented. Finally, adverse events and reinterventions were recorded.

If a patient missed a follow-up visit, the FIQL questionnaire was sent by mail, and other data were obtained by telephone interview if possible.

Statistical Methods
-------------------

Statistical analyses were performed using R statistical software ([www.r-project.org](www.r-project.org)). A 2-sided *P*-value \< 0.05 was considered statistically significant. Continuous data are expressed as the mean ± SD or 95% confidence interval (CI) and as medians with ranges. The Chi-square test, Student's *t* test, and the Wilcoxon test were used to compare proportions and continuous variables. In the regression analysis, all *P*-values were computed by likelihood ratio tests. Wald-type CIs were estimated. Missing data were imputed using the last observation carried forward, and the random survival forest method.[@b22-jnm-25-159] Successfully sustained SNM therapy was the primary outcome. Success was assessed from the time of implantation until permanent discontinuation of SNM therapy. If SNM therapy was discontinued due to reasons unrelated to the SNM procedure, these events were censored. Permanent SNM discontinuation was assessed by a Kaplan-Meier analysis. Univariate and multivariate Cox regression analysis were performed with adjustment for age, sex, existence and cause of incontinence, and lead position. Based on the Akaike information criterion, irrelevant variables were eliminated from the full Cox regression model by backward variable selection. To assess subjective outcomes in the questionnaire over time, a locally weighted scatterplot smoothing (LOWESS) regression analysis was performed.[@b23-jnm-25-159]

Results
=======

Patient Characteristics
-----------------------

In this trial, 101 patients (82 females) were included. The median age was 64 (range, 18--81) years. The indication for SNM therapy was constipation in 16 patients (15.8%), FI in 73 (72.3%), and both FI and constipation in 12 (11.9%), with FI being the leading symptom. The patient characteristics are summarized in [Table 1](#t1-jnm-25-159){ref-type="table"}. Patients with constipation were classified as either slow transit (n = 11), outlet obstruction (n = 15) or both outlet obstruction and slow transit (n = 2). There was no difference in the success of the screening or in lasting success between the subgroups with constipation (*P* \> 0.05). Subgroups of constipation were therefore not further differentiated.

Screening Success
-----------------

Definitive SNM implantation was performed in 79 patients (78.2%) ([Table 1](#t1-jnm-25-159){ref-type="table"}). Screening was successful in 100% of patients with both FI and constipation (n = 12), 80.8% (59/73) with FI, and 50% (8/16) with constipation. Isolated constipation (*P* = 0.004) was the only negative predictor for screening success.

Sacral neuromodulation Success Over Time
----------------------------------------

At the end of follow-up, 57 patients (72.2%) had successfully sustained SNM therapy. The mean follow-up was 4.4 ± 3.0 years, and the median follow-up was 4.2 (0.1--10.0) years. The general 5-year and 7-year SNM success rates were 75.1% (95% CI, 64.8--86.7%) and 69.8% (95% CI, 58.5--83.2%), respectively. The SNM-specific (censoring 4 patients for discontinuation due to reasons unrelated to SNM therapy) 5-year and 7-year success rates were 81.7% (95% CI, 72.6--91.9%) and 76.1% (95% CI, 65.2--88.7%), respectively ([Fig. 1A](#f1-jnm-25-159){ref-type="fig"}). All the following success rates describe specific SNM success. The 5-year success rates were 87.3% (95% CI, 78.1--97.6%) for FI alone, 31.2% (95% CI, 10.2--95.5%) for constipation, and 91.7% (95% CI, 77.3--100.0%) for patients with both FI and constipation. The yearly rates for SNM success are shown in [Table 2](#t2-jnm-25-159){ref-type="table"}. When analyzed jointly, 88.2% (95% CI, 80.1--97.0%) of FI patients with or without constipation had sustained successful therapy for over 5 years, and 85.3% (95% CI, 76.1--95.7%) of these patients had sustained successful therapy for over 7 years.

The 5-year success rates for the different etiologies of FI were 84.4% (95% CI, 71.5--99.8%) for FI caused by a sphincter defect (n = 29), 100.0% (95% CI, 54.1--100.0%) for idiopathic FI (n = 6), 100.0% (95% CI, 59.0--100.0%) for multifactorial FI (n = 7), 87.5% (95% CI, 67.3--100.0%) for FI due to a neurogenic disorder (n = 11), and 83.7% (95% CI, 64.5--100.0%) for FI after pelvic surgery (n = 18). There was no significant difference regarding the etiologies in patients with a combination of FI and constipation compared to those with FI alone (*P* = 0.092). Of the 22 patients in whom therapy was terminated after implantation, 4 patients discontinued therapy for reasons not related to SNM (death, abdomino-perineal resection due to cancer, no constipation after gastric bypass, and Hartmann's procedure because of perforated diverticulitis). In the remaining 18 patients, treatment termination was due to a lack or loss of efficacy (n = 15), infection (n = 1), pain/spinal infarct not related to SNM (due to spinal stenosis) (n = 1), and withdrawn consent (n = 1).

The rate of successful treatment on an intention-to-treat (ITT) basis was 70.1% (95% CI, 60.3--81.4%) for patients suffering from FI at 5 years and 67.9% (95% CI, 57.7--79.9%) at 7 years including patients with unsuccessful screening and SNM termination for reasons unrelated to SNM therapy.

[Figure 2](#f2-jnm-25-159){ref-type="fig"} shows an ITT analysis comparing patients with isolated FI, isolated constipation and FI and constipation combined. The results for isolated constipation were significantly worse than those for isolated FI (*P* \< 0.001). Furthermore, the outcomes for patients with a combination of FI and constipation were significantly better than those for isolated FI (*P* = 0.041).

Battery Life
------------

In 94.9% of patients (n = 75), an InterStim II IPG was implanted. For all types of stimulators, the median battery life was 6.2 years. A battery change was required in 23 patients (29.1%). The 5-year battery (InterStim I and II) survival rate was 76.2% (95% CI, 63.8--90.9%) and the 7-year survival rate was 32.7% (95% CI, 19.6--54.5%). For the InterStim II battery (n = 75 and 23 events), the median survival was 5.9 years (95% CI, 5.3--6.8 years) with a 7-year survival rate of 25.1% (95% CI, 13.0--48.6%) ([Fig. 1B](#f1-jnm-25-159){ref-type="fig"}). In all patients, SNM therapy was successfully sustained after a battery change.

Multivariate Analysis of Sacral Neuromodulation Success
-------------------------------------------------------

In the univariate analysis, the risk for SNM termination was significantly increased in patients with isolated constipation compared to patients with FI (*P* = 0.001) ([Table 3](#t3-jnm-25-159){ref-type="table"}). This association was confirmed in a multivariate analysis with all variables included (full model) and after backward variable selection (*P* \< 0.001) ([Table 3](#t3-jnm-25-159){ref-type="table"}). In the multivariate analysis, the risk of SNM termination was increased with electrode positioning at S4 compared to positioning at S3 (*P* = 0.042).

Symptom Improvement
-------------------

Symptom improvement \> 50% was observed in 73.1% (95% CI, 66.8--79.5%) of all patients after one year and 84.3% (95% CI, 64.1--100.0%) after 7 years.

While for patients with FI the SNM success rate stayed above 80% for the whole follow-up period, no patient with isolated constipation maintained successful treatment after 6 years ([Fig. 3](#f3-jnm-25-159){ref-type="fig"}). In patients with FI, several parameters were available to evaluate the effect of SNM therapy. Involuntary evacuations per week decreased \> 50% in 82.7% (95% CI, 76.3--89.1%) of patients after 1 year and in 78.6% (95% CI, 59.1--98.0%) of patients after 7 years. [Figure 4](#f4-jnm-25-159){ref-type="fig"} shows the significant (*P* \< 0.01) and lasting improvement in terms of the Wexner score, involuntary evacuations per week and the FIQL questionnaire results. There is a trend towards a more distinct effect of SNM in terms of the Wexner score and involuntary evacuations per week in patients with nonneurogenic FI. For both nonneurogenic and neurogenic FI, the effect of SNM can be sustained over time. There was a significant improvement in patient QoL in all categories of the FIQL (lifestyle, coping/behavior, depression, and embarrassment). In patients with successful SNM therapy, a sustained effect was not only seen in terms of improvement in symptoms but also in terms of QoL.

Complications
-------------

During follow-up, 57 complications occurred in 33 patients (41.8%). Of these, 40 complications required surgery in 24 patients (30.4%), whereas 17 complications in 14 patients (17.7%) were treated conservatively ([Table 4](#t4-jnm-25-159){ref-type="table"}). Some patients had more than one complication. The most common complication was a broken or displaced lead in 22 cases in 16 patients. There were 13 broken leads that all required surgery. Of the 9 cases of lead displacement, all but 2 required surgery. There was no significant association between lead complications and lead position (10 of 43 \[23.3%\] for S3 and 6 of 36 \[16.7%\] for S4; *P* = 0.468) or the side of definitive implantation (4 of 22 \[18.2%\] for the left side, 7 of 39 \[17.9%\] for the right side, 5 of 18 \[27.8%\] for both sides; *P* = 0.760). SNM therapy was discontinued in only one patient after reoperation. This patient had her device removed because of an infection and decided against implantation afterwards. During the screening phase, the complication rate was 6.9%. After SNM implantation, 50.0% of all complications occurred within 18 months, and 75.0% occurred within 35 months.

[Figure 5](#f5-jnm-25-159){ref-type="fig"} compares the SNM success rates in patients after IPG implantation with and without complications requiring surgical revisions. The 5-year success rate for patients without any surgical complications was 78.4% (95% CI, 67.2--91.4%) and was 89.0% (95% CI, 75.3--100.0%) for patients with a complication requiring surgical reintervention (*P* = 0.643). At 7 years, the success rates for patients without any surgical complications and those with a complication requiring surgical revision were 74.2% (95% CI, 61.6--89.5%) and 80.9% (95% CI, 62.9--100.0%), respectively.

Discussion
==========

This study shows that SNM improves FI in an effective and lasting way. The effect is especially high in patients with both FI and constipation. In contrast, the effect wears off over time in patients with only constipation. Apart from electrode positioning at S3, no other factors could be found to influence the sustainability of SNM success. Surgical reinterventions were necessary in approximately 30% of patients, but SNM therapy could be maintained successfully. Furthermore, the InterStim II stimulator was found to have a battery life of approximately 6 years.

Successful SNM treatment for patients with FI has been demonstrated in several studies regardless of the cause of FI.[@b13-jnm-25-159],[@b14-jnm-25-159],[@b24-jnm-25-159]--[@b26-jnm-25-159] Success rates during the screening phase of 66.8--90.0% have been reported.[@b12-jnm-25-159],[@b13-jnm-25-159],[@b26-jnm-25-159] Recently published reports with follow-up periods of over 36 months have shown that the treatment effect and QoL improvement can be sustained for 5--10 years.[@b12-jnm-25-159]--[@b14-jnm-25-159] A reduction \> 50% in involuntary evacuations per week has been described in 75--84% of patients.[@b9-jnm-25-159],[@b27-jnm-25-159] Furthermore, the Wexner score was reduced from 16 to 7,[@b26-jnm-25-159] concurrent with significant improvements in all categories of the FIQL.[@b9-jnm-25-159],[@b13-jnm-25-159] These results were confirmed by this study. In a systematic review from 2013 involving 61 eligible studies analyzing the effectiveness of neuromodulation in FI, most studies had only short- or midterm follow-up periods.[@b9-jnm-25-159] The median number of patients in trials with long-term follow-up was 21 (range: 9--91). Long-term follow-up studies with a high number of patients are scarce. The largest recent multicenter study by Altomare et al[@b26-jnm-25-159] included 228 patients. In that study and in the systematic review mentioned before, the success rates based on ITT were 48% and 54%, respectively, compared to the 5-year ITT success rate for FI of 70% in this study. The reasons for this superior result are unclear but might be explained by the rigorous follow-up and the consequent maintenance interventions.

This seems to be the first study to assess the sustainability of SNM success by including patients with constipation and FI. The role of SNM for constipated patients is currently debated. This study and 2 other studies showed no difference in the outcome of SNM therapy in different subtypes of constipation. Nevertheless, in all studies, there were relatively few cases.[@b28-jnm-25-159],[@b29-jnm-25-159] A European consensus paper stated that further trials are needed and that this therapy is less effective for constipation than for FI.[@b15-jnm-25-159] Overall, the reported results are rather disappointing, although midterm success rates of up to 90% have been shown after permanent SNM implantation.[@b30-jnm-25-159] Furthermore, SNM therapy was effective for constipation in a double-blind crossover trial in which placebo effects could be ruled out.[@b31-jnm-25-159] However, a larger similar randomized controlled trial showed no effect on constipation, whether the stimulation was active or not.[@b32-jnm-25-159] There are hardly any long-term results. A recent long-term study following 45 constipated patients after permanent implantation found that on average constipation symptoms were improved in the 18 patients available at a 5-year follow-up.[@b29-jnm-25-159] This analysis observed a significantly lower success rate in the percutaneous nerve evaluation and in the sustainability of SNM success in patients with isolated constipation. In all patients with isolated constipation, SNM therapy was terminated during follow-up. In patients with both constipation and FI, the therapeutic success was significantly (*P* = 0.041) better than in patients with FI alone. One possible explanation is that the effect of SNM therapy accumulates because the symptoms of both FI and constipation improve. This is most likely if the symptoms have a common origin. It is known that rectal hyposensitivity is seen in patients with FI and constipation.[@b33-jnm-25-159] SNM therapy can normalize the rectal sensory threshold in patients with rectal hyposensitivity and reduce symptoms effectively.[@b34-jnm-25-159]

In addition to the indications for SNM therapy, this trial identified only lead positioning at S3 as a factor for success. The S3 nerve contains efferent and afferent fibers from the anterior part of the levator ani and sensory fibers from the perineum and the genitals. Stimulation at S2 and occasionally at the level of S3 might result in muscle cramping in the legs.[@b35-jnm-25-159],[@b36-jnm-25-159] S4 affects the posterior part of the levator ani with sensation around the anus and has no motor effects on the legs.[@b37-jnm-25-159] Currently, there is no recommendation regarding whether the S3 or the S4 foramen should be preferred.[@b15-jnm-25-159] To our knowledge, only one other study has analyzed the influence of S3 vs S4 electrode placement on success.[@b38-jnm-25-159] This study showed no difference in the effect on incontinence. However, the proportion of patients implanted at S4 was minor, and no multivariate analysis was performed. In accordance with other authors, no other predictors of success were found. The cause of FI and the extent of sphincter lesions do not seem to limit treatment success.[@b26-jnm-25-159],[@b39-jnm-25-159],[@b40-jnm-25-159]

Several reinterventions were due to expected maintenance rather than to adverse events. Since rechargeable batteries are expensive and need a long recharging time, they are not yet used routinely. All patients with nonrechargeable IPGs need a battery change after a number of years. Using Kaplan-Meier analysis, we determined that median battery life of the InterStim II IPG was 5.9 years, which corresponds well with the results of a smaller study reporting a mean battery life of 5.4 years; however, that study did not indicate the type of stimulator that was used.[@b19-jnm-25-159] Another larger study included InterStim I IPGs and the Kaplan-Meier curve for the InterStim II IPG did not reach the 50% threshold to calculate the median battery life. By extrapolation, a median survival of approximately 6.5 years might be expected.[@b41-jnm-25-159] For the InterStim I stimulator, a median lifespan of 8.8 years was found. Otherwise, relatively little data are available on battery life. The expected battery life is essential to estimate the maintenance effort and the cost required to sustain SNM therapy. This might impact the decision regarding which IPG type fits each individual patient. In accordance with the previously mentioned study, this trial showed that SNM therapy is still successful after replacing the IPG.[@b41-jnm-25-159]

It is challenging to evaluate adverse events and reinterventions, since most events occur several years after implantation. Most studies have focused on the efficacy of SNM therapy, and many did not describe adverse events in detail. A recent literature review showed a wide variation in adverse events.[@b18-jnm-25-159] In one study with detailed information on adverse events, a complication rate of 93% over a period of 5 years was reported.[@b42-jnm-25-159] In the long-term follow-up of an American multicenter study on SNM, 26.3% of SNM patients required reoperation to treat adverse events excluding battery changes.[@b43-jnm-25-159] A British study reported reoperations in 28.8% of their patients after a shorter follow-up period.[@b19-jnm-25-159] This analysis shows that, in most cases, SNM therapy can be sustained by reinterventions. In many cases, adverse events such as infections or IPG dislocation can be successfully managed. Lead replacement led to a worse treatment effect in a recent study,[@b44-jnm-25-159] while in the present study, the success rate after surgical revision was at least as good as that in patients without revision.

In the following the strengths and limitations of the study are discussed. This study is one of the largest single-center follow-up analyses evaluating the sustainability of SNM success. Furthermore, this study included patients with FI and constipation.

A limitation of the study is the retrospective nature, which presents a certain risk of bias. There were relatively few patients with constipation alone. However, reports on constipation with a higher caseload are rare, especially those with mid- and long-term follow-up periods. Furthermore, the treatment success in patients with constipation could only be assessed by subjective improvement in symptoms.

In conclusion, this study shows that SNM is an effective and sustainable treatment for FI regardless of its etiology. The outcome of SNM is even better when FI is accompanied by constipation. In patients with isolated constipation, the initial success rate is low and decreases over time. Therefore, the indications for SNM therapy should be restrained in patients with isolated constipation. Additionally, a lead position at S3 led to improved outcomes and should be preferred to S4 positioning if the response to stimulation is similar during nerve evaluation. Adverse events are common, and reinterventions must be expected in the long term. However, such reoperations are worthwhile as they sustain the treatment success. Before beginning SNM therapy, patients should be informed about the necessity for long-term follow-up, the possibility of operative revisions and the need for a battery change after 5--7 years.
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![Kaplan-Meier plots for sacral neuromodulation success and battery survival. (A) Sacral neuromodulation (SNM) success over time. Patients who discontinued SNM therapy due to reasons unrelated to SNM therapy were censored. (B) InterStim II battery life (InterStim I batteries were excluded). Kaplan-Meier plots including all patients (fecal incontinence and constipation) with an implanted permanent pulse generator with pointwise 95% CIs depicted. The number of patients at risk is given below each plot.](jnm-25-159f1){#f1-jnm-25-159}

![Successful sacral neuromodulation (SNM) test and therapy according to the indications. Intention-to-treat analysis comparing patients with isolated fecal incontinence (FI), isolated constipation and the combination of FI and constipation. Kaplan-Meier plot for successful SNM tests and therapy in the 3 subgroups. *P*-values were estimated with likelihood ratio tests. HR, hazard ratio; Ref, reference.](jnm-25-159f2){#f2-jnm-25-159}

![(A) Successful sacral neuromodulation (SNM) therapy. Kaplan-Meier plot comparing patients with or without fecal incontinence (FI). (B) Subjective improvement in patients with isolated constipation and patients with FI shown in a scatter plot (each mark represents an individual patient). Patients who discontinued SNM therapy due to reasons unrelated to SNM therapy were censored. The number of patients at risk is given below each plot for both groups. Hazard ratio (HR) for isolated constipation. *P*-values were estimated with likelihood ratio tests. Patients after permanent implantation were included; no incontinence = isolated constipation.](jnm-25-159f3){#f3-jnm-25-159}

![Subjective outcomes (A) change in Wexner scores before and after sacral neuromodulation (SNM) therapy (fecal incontinence \[FI\] patients only, n = 71). (B) Change in the number of involuntary evacuations per week (FI patients only, n = 71). (C) Change in the Fecal Incontinence Quality of Life (FIQL) score (all patients, n = 79). (D) Percent of patients with \> 50% improvement in involuntary evacuations per week (FI patients only, n = 71). *P*-values were estimated with the Wilcoxon test. (A--C) left: box plots comparing preoperative (baseline) and postoperative results. (A--C) right and (D): follow-up treatment success of patients with ongoing SNM therapy. OP, operative.](jnm-25-159f4){#f4-jnm-25-159}

![Sacral neuromodulation (SNM) success for patients with and without complications requiring surgery shown in a Kaplan-Meier plot. Patients who discontinued SNM therapy due to reasons unrelated to the SNM therapy were censored. The number of patients at risk is given below each plot. Hazard ratio (HR) for complications requiring surgery. *P*-values were estimated with likelihood ratio tests. Patients after permanent implantation were included.](jnm-25-159f5){#f5-jnm-25-159}

###### 

Patient Characteristics and Bias for Implantation

  Patient characteristics             Total (n = 101)   Unsuccessful screening[a](#tfn1-jnm-25-159){ref-type="table-fn"} (n = 22)   SNM implant (n = 79)   *P*-value
  ----------------------------------- ----------------- --------------------------------------------------------------------------- ---------------------- -------------------------------------------------
  Sex                                                                                                                                                      
                                                                                                                                                           
   Female                             82 (81.2%)        16 (72.7%)                                                                  66 (83.5%)             0.251[b](#tfn2-jnm-25-159){ref-type="table-fn"}
   Male                               19 (18.8%)        6 (27.3%)                                                                   13 (16.5%)             
  Age (yr)                            61.6 (13.5)       64.2 (12.6)                                                                 60.9 (13.8)            0.299[c](#tfn3-jnm-25-159){ref-type="table-fn"}
  Incontinence/constipation                                                                                                                                
   Incontianence                      73 (72.3%)        14 (63.6%)                                                                  59 (74.7%)             0.004[a](#tfn1-jnm-25-159){ref-type="table-fn"}
   Constipation                       16 (15.8%)        8 (36.4%)                                                                   8 (10.1%)              
   Both                               12 (11.9%)        0 (0.0%)                                                                    12 (15.2%)             
  Cause of incontinence                                                                                                                                    
   No incontinence                    16 (15.8%)        8 (36.4%)                                                                   8 (10.1%)              0.015[d](#tfn4-jnm-25-159){ref-type="table-fn"}
   Sphincter defect                   31 (30.7%)        2 (9.1%)                                                                    29 (36.7%)             
   Idiopathic                         6 (5.9%)          0 (0.0%)                                                                    6 (7.6%)               
   Multifactorial                     9 (8.9%)          2 (9.1%)                                                                    7 (8.9%)               
   Neurogenic disorder                14 (13.9%)        3 (13.6%)                                                                   11 (13.9%)             
   Pelvic surgery                     25 (24.8%)        7 (31.8%)                                                                   18 (22.8%)             
  Type of incontinence                                                                                                                                     
   No incontinence                    16 (15.8%)        8 (36.4%)                                                                   8 (10.1%)              0.007[d](#tfn4-jnm-25-159){ref-type="table-fn"}
   Nonneurogenic                      62 (61.4%)        9 (40.9%)                                                                   53 (67.1%)             
   Neurogenic                         23 (22.8%)        5 (22.7%)                                                                   18 (22.8%)             
  Constipation                                                                                                                                             
   No                                 73 (72.3%)        14 (63.6%)                                                                  59 (74.7%)             0.306[b](#tfn2-jnm-25-159){ref-type="table-fn"}
   Yes                                28 (27.7%)        8 (36.4%)                                                                   20 (25.3%)             
  Type of constipation                                                                                                                                     
   No constipation                    73 (72.3%)        14 (63.6%)                                                                  59 (74.7%)             0.690[d](#tfn4-jnm-25-159){ref-type="table-fn"}
   Outlet obstruction                 15 (14.9%)        4 (18.2%)                                                                   11 (13.9%)             
   Slow transit                       11 (10.9%)        3 (13.6%)                                                                   8 (10.1%)              
   Both                               2 (2.0%)          1 (4.5%)                                                                    1 (1.3%)               
  Urinary incontinence                                                                                                                                     
   No                                 78 (77.2%)        19 (86.4%)                                                                  59 (74.7%)             0.248[b](#tfn2-jnm-25-159){ref-type="table-fn"}
   Yes                                23 (22.8%)        3 (13.6%)                                                                   20 (25.3%)             
  Previous sphincteroplasty                                                                                                                                
   No                                 90 (89.1%)        20 (90.9%)                                                                  70 (88.6%)             0.759[b](#tfn2-jnm-25-159){ref-type="table-fn"}
   Yes                                11 (10.9%)        2 (9.1%)                                                                    9 (11.4%)              
  Other previous therapy                                                                                                                                   
   No                                 81 (80.2%)        16 (72.7%)                                                                  65 (82.3%)             0.320[b](#tfn2-jnm-25-159){ref-type="table-fn"}
   Yes                                20 (19.8%)        6 (27.3%)                                                                   14 (17.7%)             
  Screening results                                                                                                                                        
   Lead position                                                                                                                                           
    S3                                54 (53.5%)        12 (54.5%)                                                                  42 (53.2%)             1.000[d](#tfn4-jnm-25-159){ref-type="table-fn"}
    S4                                43 (42.6%)        9 (40.9%)                                                                   34 (43.0%)             
    Both/unknown                      4 (4.0%)          1 (4.5%)                                                                    3 (3.8%)               
  Complications during screening                                                                                                                           
   No                                 94 (93.1%)        20 (90.9%)                                                                  74 (93.7%)             0.652[b](#tfn2-jnm-25-159){ref-type="table-fn"}
   Yes                                7 (6.9%)          2 (9.1%)                                                                    5 (6.3%)               
  Subjective baseline data                                                                                                                                 
   Wexner score                       13.7 (6.0)        11.8 (8.3)                                                                  14.2 (5.2)             0.210[c](#tfn3-jnm-25-159){ref-type="table-fn"}
   Involuntary evacuations per week   10.6 (21.4)       7.0 (5.5)                                                                   11.6 (23.9)            0.118[c](#tfn3-jnm-25-159){ref-type="table-fn"}
   Ability to defer defecation                                                                                                                             
    \< 1 min                          66 (65.3%)        14 (63.6%)                                                                  52 (65.8%)             0.058[d](#tfn4-jnm-25-159){ref-type="table-fn"}
    1 to \< 5 min                     13 (12.9%)        0 (0.0%)                                                                    13 (16.5%)             
    5 to 15 min                       1 (1.0%)          0 (0.0%)                                                                    1 (1.3%)               
    \> 15 min                         21 (20.8%)        8 (36.4%)                                                                   13 (16.5%)             
  FIQL lifestyle                      2.5 (0.5)         2.4 (0.8)                                                                   2.5 (0.3)              0.574[c](#tfn3-jnm-25-159){ref-type="table-fn"}
  FIQL coping/behavior                1.8 (0.5)         2.1 (0.7)                                                                   1.8 (0.3)              0.033[c](#tfn3-jnm-25-159){ref-type="table-fn"}
  FIQL depression                     2.3 (0.3)         2.3 (0.5)                                                                   2.3 (0.3)              0.972[c](#tfn3-jnm-25-159){ref-type="table-fn"}
  FIQL embarrassment                  2.3 (0.4)         2.6 (0.5)                                                                   2.2 (0.4)              0.008[c](#tfn3-jnm-25-159){ref-type="table-fn"}

Unsuccessful screening was defined as a less than 50% symptom improvement.

Chi-Square test.

*t* test.

Chi-Square test, Monte-Carlo simulated.

SNM, sacral neuromodulation; FIQL, fecal incontinence quality of life.

Values are expressed as n (%) or mean (SD).

###### 

Yearly Rates for Sacral Neuromodulation Success in Patients With Definitive Sacral Neuromodulation Implantation

  SNM-success   FI only (n = 59)              Constipation only (n = 8)    FI ± constipation (n = 71)    FI + constipation (n = 12)    All patients (n = 79)
  ------------- ----------------------------- ---------------------------- ----------------------------- ----------------------------- -----------------------------
  1-year        98.2% (94.7--100.0, n = 54)   87.5% (67.3--100.0, n = 7)   97.0% (93.1--100.0, n = 64)   91.7% (77.3--100.0, n = 10)   96.0% (91.7--100.0, n = 71)
  2-year        92.5% (85.8--99.9, n = 45)    62.5% (36.5--100.0, n = 5)   92.4% (86.1--99.0, n = 55)    91.7% (77.3--100.0, n = 10)   89.1% (82.3--96.5, n = 60)
  3-year        90.3% (82.6--98.8, n = 39)    62.5% (36.5--100.0, n = 5)   90.6% (83.6--98.1, n = 48)    91.7% (77.3--100.0, n = 9)    87.5% (80.2--95.5, n = 53)
  4-year        90.3% (82.6--98.8, n = 33)    31.2% (10.2--95.5, n = 1)    90.6% (83.6--98.1, n = 41)    91.7% (77.3--100.0, n = 8)    83.8% (75.4--93.2, n = 42)
  5-year        87.3% (78.1--97.6, n = 28)    31.2% (10.2--95.5, n = 1)    88.2% (80.1--97.0, n = 36)    91.7% (77.3--100.0, n = 8)    81.7% (72.6--91.9, n = 37)

SNM, sacral neuromodulation; FI, fecal incontinence; n, number of patients available for follow-up.

The yearly success rates are shown in % with 95% point-wise CIs and the number of patients at risk. They were estimated using the Kaplan-Meier Method.

###### 

Risk Factors for Sacral Neuromodulation Failure

  Patient characteristics   Unadjusted[a](#tfn9-jnm-25-159){ref-type="table-fn"}   Cox regression, full model[b](#tfn10-jnm-25-159){ref-type="table-fn"}   Cox regression, variable selection[c](#tfn11-jnm-25-159){ref-type="table-fn"}                                  
  ------------------------- ------------------------------------------------------ ----------------------------------------------------------------------- ------------------------------------------------------------------------------- ---------- ------------------- ----------
  Age                       1.01 (0.97--1.05)                                      0.535                                                                   1.03 (0.98--1.08)                                                               0.165      \-                  \-
  Sex                                                                                                                                                                                                                                                                     
   Female                   reference                                              0.940                                                                   reference                                                                       0.800      \-                  \-
   Male                     1.06 (0.24--4.66)                                                                                                              0.82 (0.17--3.90)                                                                          \-                  \-
  Indication                                                                                                                                                                                                                                                              
   Constipation only        reference                                              0.001                                                                   reference                                                                       \< 0.001   reference           \< 0.001
   Neurogenic FI            0.18 (0.04--0.92)                                                                                                              0.11 (0.02--0.61)                                                                          0.13 (0.03--0.70)   
   Nonneurogenic FI         0.09 (0.03--0.30)                                                                                                              0.06 (0.02--0.21)                                                                          0.08 (0.02--0.25)   
  Lead position                                                                                                                                                                                                                                                           
   S3                       reference                                              0.117                                                                   reference                                                                       0.033      reference           0.042
   S4                       2.13 (0.82--5.49)                                                                                                              2.94 (1.08--8.01)                                                                          2.72 (1.04--7.15)   

Univariate Cox regression analysis.

Multivariable Cox regression analysis full model.

Backward variable selection from the full model confirmed all prognosticators.

Likelihood ratio tests.

HR, hazard ratio; FI, fecal incontinence; S3, sacral foramina 3; S4, sacral foramina 4.

###### 

Number of Complications, Their Management and Time to First Occurrence in Patients After Sacral Neuromodulation Implantation

  Type of complication                                                         Conservative management (number of complications)   Surgical management (number of complications)   Time to complication after implantation (mean ± SD, days)
  ---------------------------------------------------------------------------- --------------------------------------------------- ----------------------------------------------- -----------------------------------------------------------
  Broken or dislocated lead (n =16)                                            2                                                   20                                              898 ± 873
  Infection (n = 10)                                                           5                                                   9                                               249 ± 497
  Pain or dysesthesia (n = 6)                                                  5                                                   4                                               859 ± 687
  IPG dislocation (n = 5)                                                      1                                                   4                                               533 ± 531
  Constipation (n = 3)                                                         3                                                   0                                               173 ± 233
  Sudden loss of efficacy[a](#tfn14-jnm-25-159){ref-type="table-fn"} (n = 3)   1                                                   3                                               485 ± 379

There was no reason found or recorded for the instantaneous loss of effect.

IPG, internal permanent pulse generator.
